Sponsor hub

Emory University clinical trial failures

Review 99 stopped clinical trials from Emory University, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 6 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials99
Likely biological signals6
Shown below99

Dominant stop reasons

OPERATIONAL
59
OTHER/UNKNOWN
34
SAFETY
4
EFFICACY/FUTILITY
2

Notable sponsors

Emory University
99

Related phases

Phase II
39
Phase IV
22
Phase I
17
Phase III
9
Unknown
8

Crawlable stopped-trial records

Open Explore

Showing up to 99 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT03523156: Trachoma Elimination Study by Focused Antibiotic (TESFA)

Phase IV Trachoma trial by Emory University. Stop reason: OTHER/UNKNOWN.

The Trachoma Elimination Study by Focused Antibiotic (TESFA): The Impact of an Enhanced Antibiotic Treatment Regimen on Trachoma in Amhara, Ethiopia is withdrawn due to severe delays and continued insecurity in the Amhara region of Ethiopia.

NCT03408340: Paravertebral Nerve Blocks in Neonates

Phase IV Congenital Heart Disease trial by Emory University. Stop reason: OPERATIONAL.

The study activities were suspended due to COVID-19, and the interim analysis did not yield positive results once resumed.

NCT04766996: PROUD Study - Preventing Opioid Use Disorders

Phase IV Anesthesia trial by Emory University. Stop reason: OTHER/UNKNOWN.

Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.

NCT02924389: Dolutegravir in Reservoirs

Phase IV HIV trial by Emory University. Stop reason: OPERATIONAL.

This study terminated early due to the ongoing covid-19 pandemic making it unsafe to recruit participants for in-person visits. Participants are living with HIV who are antiretroviral therapy-naive and are at high risk of COVID-19 complications.

NCT04326439: AflacLL1901 (CHOA-AML)

Phase II Acute Myeloid Leukemia trial by Emory University. Stop reason: OTHER/UNKNOWN.

Due to unforeseen circumstances, the study team was limited in enrolling patients on this trial; thus, it was terminated.

NCT01369147: The Energy Dose Study

Phase II Critical Illness trial by Emory University. Stop reason: OPERATIONAL.

This study was halted pending additional funding and ultimately was terminated due to difficulties with ongoing recruitment, etc.

NCT01933269: FACBC for Head and Neck Cancers

Early Phase I Cancers of the Head and Neck trial by Emory University. Stop reason: OTHER/UNKNOWN.

Change in Principal Investigator and protocol revisions delayed study start and ultimately the decision was made to cancel the study.